Jon Gutman

University of Colorado Anschutz Medical Campus

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Mark L. Laudenslager

University of Colorado Anschutz Medical Campus

Teresa L. Simoneau

University of Colorado Anschutz Medical Campus

Kristin Kilbourn

University of Colorado Denver

Susan K. Mikulich‐Gilbertson

American Heart Association

Benjamin W. Brewer

University of Colorado Anschutz Medical Campus

Peter A. McSweeney

Colorado Blood Cancer Institute

Clayton A. Smith

University of Colorado Anschutz Medical Campus

Elizabeth Burke

Mesoblast (United States)

Maria L. Amaya

University of Colorado System

Richard D. Zane

University of Colorado Health

Cooperative Institutions

University of Colorado Denver

University of Colorado Anschutz Medical Campus

University of Colorado Cancer Center

University of Colorado Health

Instituto de Liderazgo Simone de Beauvoir

University of Colorado System

University of Colorado Hospital

University of Denver

Duke Medical Center

Optum (United States)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Using a Program to Lower Stress for Caregivers of Patients With Cancer Who Have Received Stem Cell Transplants

Mark L. Laudenslager Teresa L. Simoneau Susan K. Mikulich‐Gilbertson Benjamin W. Brewer Kristin Kilbourn

What was the research about?After having a stem cell transplant to treat cancer, patients often need help from a full-time caregiver at home.Support from a caregiver is important to a patient's recovery.But being a caregiver can be stressful.Stress management programs for caregivers may improve their well-being.Having a caregiver who is less stressed may also improve patients' quality of life. How can people use the results?Hospitals can look at these results when deciding on ways to help lower caregivers' stress.

10.25302/1.2020.ce.13086208

Cite

Citations (0)

Memorial

Matt Clausen Jon Gutman

No abstract available.

10.1145/1179196.1179249

Cite

Citations (0)

A randomized control trial of stress management for caregivers of stem cell transplant patients: Effect on patient quality of life and caregiver distress

Psycho-Oncology (2019)

Mark L. Laudenslager Teresa L. Simoneau Susan K. Mikulich‐Gilbertson Crystal Natvig Benjamin W. Brewer

Abstract Background Psychological interventions reduce caregiver distress (CG‐distress). Less distress in caregivers may contribute to improved patient quality of life (QoL), but empirical evidence is lacking. Will a caregiver stress management intervention improve patient QoL? Methods In this replication study, we randomized 155 allogeneic hematopoietic stem cell transplant (Allo‐HSCT) patients and caregivers to PsychoEducation, Paced Respiration, and Relaxation (PEPRR) or enhanced treatment as usual (eTAU). We provided PEPRR over 3 months following transplant. Functional Assessment of Cancer Therapy–Bone Marrow Transplant (FACT‐BMT) evaluated patient QoL, and CG‐distress was based on depressive, anxious, and stress symptoms. Hierarchical linear models tested intervention, time, and interactions as fixed effects with participant as random effects. Results Patients whose caregivers received PEPRR did not differ on FACT‐BMT between baseline and 6 months (mean = +3.74; 95% CI, −3.54 to 11.02) compared with patients of caregivers in eTAU (mean = +3.16; 95% CI, −2.88 to 9.20) even though CG‐distress was decreased by PEPRR (mean = −0.23; 95% CI, −0.448 to −0.010) compared with those receiving eTAU (mean = +0.27; 95% CI, 0.033‐0.504) at 6 months. Conclusions PEPRR reduced CG‐distress without affecting their patient's FACT‐BMT score. The FACT‐BMT may not have distinguished unique psychological changes associated with their caregiver receiving PEPRR.

Psychoeducation

Stress Management

10.1002/pon.5126

Cite

Citations (31)

Machine Learning–Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7 + 3 Type Chemotherapy or Venetoclax/Azacitidine

JCO Clinical Cancer Informatics (2022)

Nazmul Islam Jamie S. Reuben Justin Dale Jon Gutman Christine M. McMahon

There are currently limited objective criteria to help assist physicians in determining whether an individual patient with acute myeloid leukemia (AML) is likely to do better with induction with either standard 7 + 3 chemotherapy or targeted therapy with venetoclax plus azacitidine. The study goal was to address this need by developing exploratory clinical decision support methods.Univariable and multivariable analysis as well as comparison of a range of machine learning (ML) predictors were performed using cohorts of 120 newly diagnosed 7 + 3-treated AML patients compared with 101 venetoclax plus azacitidine-treated patients.A variety of features in the two patient cohorts were identified that may potentially correlate with short- and long-term outcomes, toxicities, and other considerations. A subset of these diagnostic features was then used to develop ML-based predictors with relatively high areas under the curve of short- and long-term outcomes, hospital stays, transfusion requirements, and toxicities for individual patients treated with either venetoclax/azacitidine or 7 + 3.Potential ML-based approaches to clinical decision support to help guide individual patients with newly diagnosed AML to either 7 + 3 or venetoclax plus azacitidine induction therapy were identified. Larger cohorts with separate test and validation studies are necessary to confirm these initial findings.

Venetoclax

Azacitidine

10.1200/cci.22.00030

Cite

Citations (4)